Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 1251–1300 of 76231
Accordingly, Mr. Kanter’s Employment Agreement will expire and his employment with the Company will terminate on August 11, 2026.
On May 14, 2026, Local Bounti Corporation (the “Company”) notified Dane Almassy, the Company’s Chief Commercial Officer, that his employment with the Company ended effective May 14, 2026 (the “Separation Date”).
Effective May 8, 2026, Randall Keys ceased to serve as a member of the Board of Directors (the “Board”) of U.S. Energy Corp. (the “Company”) upon the expiration of his term
On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. (the “Company”) since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim Chief Executive Officer.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
the following named executive officers of Marine Products voluntarily resigned from any and all of their respective director, manager, or officer positions with Marine Products or any of its subsidiaries: Richard A. Hubbell, Ben M. Palmer and Michael L. Schmit.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
the following named executive officers of Marine Products voluntarily resigned from any and all of their respective director, manager, or officer positions with Marine Products or any of its subsidiaries: Richard A. Hubbell, Ben M. Palmer and Michael L. Schmit.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
the following named executive officers of Marine Products voluntarily resigned from any and all of their respective director, manager, or officer positions with Marine Products or any of its subsidiaries: Richard A. Hubbell, Ben M. Palmer and Michael L. Schmit.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc. (the "Company"), informed the Company he will be resigning effective May 29, 2026.
On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.
On May 11, 2026, Michael Woods resigned as a director of Roman DBDR Acquisition Corp. II (the “Company”), effective immediately.
On May 14, 2026, Dr. Donald G. Basile resigned as the Chief Technology Officer of the Company, effective immediately.
Mr. Bryan succeeds Nancy Buese, who by mutual agreement, stepped down from her role as Chief Financial Officer of the Company on May 11, 2026, effective as of the same date.
Tara Comonte, the Company’s former President and Chief Executive Officer, resigned from her position as President and Chief Executive Officer of the Company, effective March 31, 2026.
Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.
Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer.
On May 15, 2026, Matthew Cohen resigned from his position as Chief Executive Officer and a member of our Board of Directors, which resignation was not in connection with any disagreement regarding our operations, policies or procedures.
On May 15, 2026, Katharyn Field resigned her position as a member of our Board of Directors, which resignation was not in connection with any disagreement regarding our operations, policies or procedures.
On May 15, 2026, Matthew Cohen resigned from his position as Chief Executive Officer and a member of our Board of Directors, which resignation was not in connection with any disagreement regarding our operations, policies or procedures.
Thomas E. Wiseman, who, as previously announced, retired as chairman effective as of OVBC’s 2026 annual meeting of shareholders
the vacancy created by the previously announced retirement of David W. Thomas as of the 2026 Annual Meeting.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
On May 12, 2026, William Meissner notified the Company of his resignation as President and all other offices of and employment with the Company, which resignation will become effective on June 1, 2026.
On May 11, 2026, Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the “Company”), was notified that his employment with the Company is being terminated without cause.
Mr. Michael F. Barry, a member of the Board of Directors (the “Board”) of Quaker Chemical Corporation (the “Company”) notified the Company of his retirement from the Board, effective at the conclusion of the Board meeting on May 13, 2026.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.